REMARKS

A Notice of Allowance was mailed on January 9, 2008. Upon reviewing the pending claims, Applicants noticed that a mistake has been made in the pending claim 1. Applicants hereby submit a Request for Continued Examination, and amend claim 1 to be in commensurate with the specification. Support for the amendment to claim 1 can be found in the specification at, *e.g.*, page 1 and page 3.

According to the specification and the original claim 1, R_2 is (C_{1-4}) alkyl which is unsubstituted or substituted or substituted (C_{6-18}) aryl $(e.g., phenyl or substituted phenyl); or unsubstituted or substituted <math>(C_{6-18})$ aryl anellated with heterocyclyl (e.g., quinolinyl, or benzo(1,3)-dioxolyl). Claim 1 has been amended to reflect this clearly and accurately.

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 (617) 871-3027

Date: 04-09-2008

Mei I. Benni

Attorney for Applicants

Reg. No. 45,470